Nonsteroidal anti-inflammatory drugs (NSAIDs) reduce the risk of gastrointestinal cancers. Recently, a similar protective effect has been demonstrated by the specific cyclo-oxygenase-2 (COX-2) inhibitors. However, the exact mechanism that accounts for the anti-proliferative effect of specific COX-2 inhibitors is still not fully understood, and it is still controversial whether these protective effects are predominantly mediated through the inhibition of COX-2 activity and prostaglandin synthesis. Identification of molecular targets regulated by COX-2 inhibitors could lead to a better understanding of their pro-apoptotic and anti-neoplastic activities. In the present study, we investigated the effect and the possible molecular target of a COX-2-specific inhibitor SC-236 on gastric cancer. We showed that SC-236 induced apoptosis in gastric cancer cells. However, this effect was not dependent on COX-2 inhibition. SC-236 down-regulated the protein expression and kinase activity of PKC-b 1 , increased the expression of PKCd and PKCZ, but did not alter the expression of other PKC isoforms in AGS cells. Moreover, exogenous prostaglandins or PGE 2 receptor antagonists could not reverse the inhibition effect on PKCb 1 by SC-236, which suggested that this effect occurred through a mechanism independent of cyclo-oxygenase activity and prostaglandin synthesis. Overexpression of PKCb 1 attenuated the apoptotic response of AGS cells to SC-236 and was associated with overexpression of p21 waf1/cip1 . Inhibition of PKCb 1 -mediated overexpression of p21 waf1/cip1 partially reduced the anti-apoptotic effect of PKCb 1 . The down-regulation of PKCb 1 provides an explanation for COX-independent apoptotic effects of specific COX-2 inhibitor in cultured gastric cancer cells. We also suggest that PKCb 1 act as survival mediator in gastric cancer, and its down-regulation by COX-2 inhibitor SC-236 may provide new target for future treatment of gastric cancer.
Introduction
Cyclo-oxygenases (COXs) are the key enzymes that mediate the production of prostaglandins from arachidonic acid. Two isoforms of COX have been identified, COX-1 and COX-2. COX-1 is expressed constitutively, whereas COX-2 can be induced by a number of agents including cytokines, growth factors, and tumor promoters (Inoue et al., 1995; Simmons et al., 1989; Jones et al., 1993; Subbaramaiah et al., 1996) . Both human and animal studies suggest an important role for COX-2 in gastrointestinal tumorigenesis (Williams et al., 1996; Steinbach et al., 2000) . Up-regulation of COX-2 expression has been observed in colorectal cancer (Kargman et al., 1995) , gastric cancer (Ristimaki et al., 1997), Barrett's esophagus (Wilson et al., 1998) and pancreatic cancer (Tucker et al., 1999) . Expression of COX-2 in cultured cells confers resistance to undergo apoptosis (Tsujii and DuBois, 1995) , promotes angiogenesis (Tsujii et al., 1998; Williams et al., 2000) , stimulates metastatic potential (Tsujii et al., 1997) and modulates proliferation (Kinoshita et al., 1999) .
On the other hand, many studies have suggested that NSAIDs that inhibit COX-2 may protect against the formation of gastrointestinal cancers (Dubois and Smalley, 1996; Thun, 1996; Gupta and DuBois, 1998) . For instance, COX-2 inhibitors have been shown to inhibit proliferation of colon cancer cell and inhibit the formation of colorectal cancers in animal models through induction of apoptosis (Kawamori et al., 1998; Sheng et al., 1998; Reddy et al., 1996) . Besides colorectal cancers, COX-2 inhibitors also suppress tumor growth in nude mice bearing gastric cancer xenografts by induction of apoptosis . Although inhibition of COX-2 and subsequent decrease in prostaglandin production may contribute to the anti-cancer effect of NSAIDs (Gupta and DuBois, 1998) , others have suggested that COX-2 may not be the only target of NSAIDs. For example, NSAIDs might regulate nuclear factor-kB (NF-kB) signaling, cytochrome c, Akt (protein kinase B) or peroxisome proliferator activated receptor d (PPARd) (Weber et al., 2000; Li et al., 2001; Hsu et al., 2000; He et al., 1999) when given at high doses. Also at high concentrations, NSAIDs have anti-proliferative and pro-apoptotic effects on tumor cells that do not express COX-2 (Hanif et al., 1996; Elder et al., 1997; Grosch et al., 2001) . Therefore, it appears NSAIDs have other possible molecular targets besides COX-2.
Protein Kinase C (PKC) represents a family of closely related serine/threonine kinases (Nishizuka, 1988) that play a role in signal transduction pathways (Nishizuka, 1992) . It consists of at least 12 isoforms with different tissue expressions, substrate specificity and subcellular localization that has been shown to be related to specialized cell functions including cell growth and apoptosis (Hug and Sarre, 1993; Jaken, 1996) . Among all of the PKC isoforms, PKCb has been suggested to play an important role in the carcinogenesis and metastasis of gastrointestinal cancers (Yasui et al., 1985; Schwartz et al., 1993) . Moreover, several recent studies demonstrated that PKCb inhibitors executed anti-angiogenic and antitumor effect in gastrointestinal cancers (Teicher et al., 2001a,b; Cesaro et al., 2001) . For instance, Schwartz et al. (1995) found that the specific PKC inhibitor safingol enhanced the cytotoxic effect of Mitomycin C in gastric cancer cells by promoting drug-induced apoptosis. Another group demonstrated that a PKCb inhibitor exhibited anti-angiogenic and anti-tumor effects in human gastric cancer xenografts (Teicher et al., 2001b) . Previously, our group have reported that PKC inhibitors induced apoptosis in human gastric cancer cell lines through modulating apoptosis-related genes (Zhu et al., 1999a) and activation of PKC by the phorbol ester 12-0-tetradecanoylphorbol-13-acetate (TPA) inhibited the apoptosis induced by indomethacin in gastric cancer cells, accompanied by the upregulation of expression of p21 waf1/cip1 and downregulation of c-myc (Zhu et al., 1999b) . Besides, we also demonstrated that overexpression of PKCb 1 suppressed indomethacin-induced apoptosis in gastric cancer cells through the up-regulation of p21 waf1/cip1 (Zhu et al., 2000) . Taken together, these results indicate that PKC may be another cellular target for NSAIDs to execute its anti-tumor effect in gastric cancer.
The data outlined above led to our present studies on the effect and possible molecular target of a specific COX-2 inhibitor SC-236 in gastric cancer. Our results showed that SC-236 down-regulated PKCb 1 expression and activity. This effect was not mediated by COX-2-PGE 2 pathway. Furthermore, SC-236 induced apoptosis in gastric cancer cells through a COX-2-independent pathway. Overexpression of PKCb 1 increased expression of p21 waf1/cip1 and suppressed SC-236-induced apoptosis in gastric cancer cells. Inhibition of PKCb 1 -mediated overexpression of p21 waf1/cip1 partially reduced the anti-apoptotic effect of PKCb 1 . These results indicate that PKCb 1 is a novel target in the induction of apoptosis and anti-tumor effect by SC-236 in gastric cancer.
Results

SC-236 inhibited PKCb 1 expression and activity
Although PKC has 12 isoforms, only isoforms a, b 1 , b 2 , g, d, Z, z, e, i and m were expressed in AGS cells at detectable levels as determined by Western blot analysis (Figure 1a) . PKC isoforms l and y could not be detected. Incubation of AGS cells with 25 mM SC-236 significantly reduced the protein expression of PKCb 1 isoform detected as early as 6 h. After 12 h Figure 1 SC-236 down-regulated protein expression and kinase activity of PKCb 1 . (a) AGS cells were treated with 25 mM SC-236 and collected at different time points up to 24 h. Total cellular protein (50 mg) was analysed on 10% SDS-acrylamide gels and antibodies for PKC isoforms were used. The density of PKC isoforms was further detected by video densitometry. (b) AGS cells were treated with 25 mM SC-236 or SC-288 and collected at different time points up to 4 h. The kinase activity assay was performed as described in Materials and methods. *P50.05 treatment, the expression of PKCb 1 remained at 30% of the control. In addition, SC-236 treatment also moderately increased the expression of PKCd and Z isoform, but did not alter the expression of the other isoforms compared with the control (Figure 1a ). To detect whether down-regulation of the PKCb 1 isoform would affect the PKCb 1 activity in AGS cells, PKCb 1 kinase activity was also measured. As shown in Figure  1b , 25 mM SC-236 caused a significant decrease in kinase activity after 1 h treatment in AGS cells. This observation suggests that SC-236 inhibits both PKCb 1 expression and kinase activity.
SC-288 inhibited PKCb 1 expression and activity
To study whether SC-236 suppressed PKCb 1 expression through COX inhibition, a compound SC-288, SC-236's derivative but devoid of COX-2 inhibition activity was used. Firstly, we confirmed the effects of SC-236 and SC-288 on COX-2 by measuring COX-2 protein expression and PGE 2 production using Western blot and ELISA. As shown in Figure 2a , both COX-1 and COX-2 proteins were expressed in AGS cells, although the expression of COX-1 was much stronger than that of COX-2. After treatment with 25 mM SC-236 for 24 h, the protein expression of both COX-1 and COX-2 remained unchanged. Since COX-1 and COX-2 are the key enzymes which catalyze the first committed step in the synthesis of PGE 2 , we then determined whether SC-236 or SC-288 inhibited TNF-a induced PGE 2 production in AGS cells ( Figure 2b ). As the ELISA assay showed, the PGE 2 production was very low in the AGS culture (about 15 pg/10 5 cells). Fifty ng/ml TNF-a induced PGE 2 production to about twofold compared with the control. Pretreatment with 1 mM SC-236 significantly reduced TNF-a-induced PGE 2 production to less than 50%. With higher concentrations of SC-236, PGE 2 remained less than the detection level (510 pg/10 5 cells). On the contrary, up to 100 mM SC-288 has no effect on TNF-a-induced PGE 2 production. Then we detected the protein expression of classical PKCs after SC-288 treatment. Twenty-five mM SC-288 significantly reduced the protein expression of PKCb 1 after 12 h treatment, whereas the expression of the other PKC isoforms was unchanged ( Figure 2c ). In addition, SC-288 also inhibited the PKCb 1 kinase activity significantly after 1 h treatment ( Figure 1b) . Next, we investigated the effects of NS-398 and Nimesulide, two other specific COX-2 inhibitors, in AGS cells. As shown in Figure  3a , both NS-398 and Nimesulide had no effect of PKCb 1 expression.
Prostaglandins and PGE 2 receptor antagonists did not have any effect on PKCb 1 expression
The above results suggested that the inhibition of PKCb 1 by SC-236 might not occur through inhibition of PGE 2 synthesis. To clarify this issue, we determined the role of PGE 2 , PGH 1 and PGH 2 on the expression of PKCb 1 after SC-236 treatment. Prostaglandin H 1 is the precursor to all 1-series prostaglandins whereas Prostaglandin H 2 is the precursor to all 2-series prostaglandins. As shown in Figure 3b , exogenous prostaglandins did not reverse the inhibition of PKCb 1 expression in AGS cells. PGE 2 is known to exert its effects through binding to cell surface PGE 2 receptors (a) AGS cells were treated with 25 mM SC-236 or SC-288 and collected at different time points up to 24 h. Total cellular protein (20 mg) was analysed on 10% sodium dodecyl sulfate (SDS)-acrylamide gels and COX-1 and COX-2 proteins were identified using monoclonal antibodies. (b) Cells were plated on 24-well plates and exposed to treatment. PGE 2 content of the conditioned media was determined by ELISA. Results are mean+s.d. of triplicate assays and two experiments. (c) Cells were treated with 25 mM SC-288 and collected at different time points up to 24 h. Total cellular protein (50 mg) was analysed on 10% SDS-acrylamide gels and antibodies for PKC isoforms were used. The density of PKC isoforms was further detected by video densitometry (EP) in gastric tissue (Kunikata et al., 2001) . To further exclude the possibility that PKCb 1 is downstream of COX-2 pathway, we further investigated the role of AH6809 (an EP1 and EP2 antagonist) and SC19220 (an EP1-selective antagonist) on basal and SC-236-treated PKCb 1 expression. As shown in Figure 3c ,d, both AH6809 and SC19220 had no effect on basal or SC-236-treated PKCb 1 expression.
SC-236 induced apoptosis in gastric cancer cells
Previously we demonstrated that indomethecin induced apoptosis in AGS cells. In this study we determined whether specific COX-2 inhibitors also had proapoptotic effect in gastric cancer. As shown in Figure  4a ,b, the percentage of apoptotic cells increased in a time-and dose-dependent manner. Approximately 42.3+2.5% of the AGS cells underwent apoptosis with treatment of 50 mM SC-236 for 24 h. Apoptosis was further confirmed by agarose gel electrophoresis of genomic DNA. A characteristic pattern of nucleosomesized ladders of DNA fragments was detected after 24 h exposure to SC-236 in AGS cells (Figure 4c ). The role of PGE 2 , PGH 1 and PGH 2 on SC-236-induced apoptosis was further investigated. As shown in Figure  4d , none of the prostaglandins have any effect on COX-2 inhibitors-induced apoptosis.
Effects of PKC-b 1 on SC-236 induced apoptosis in AGS cells
The role of PKCb 1 in SC-236-induced apoptosis was further addressed using transient transfection to over- To evaluate the possible molecular mechanism of PKCb 1 involvement in SC-236 induced apoptosis, we examined the protein expression of several apoptosisrelated genes, i.e. p53, p21
waf1/cip1 , c-myc, bax, bcl-2 and p27 kip1 after transfection with PKCb 1 . As shown in Figure 6a , the protein level of p21 waf1/cip1 was strongly upregulated in PKCb 1 -transfected cells compared with the control. After exposure to 25 mM SC-236 for 12 h, there were no alterations in p21 waf1/cip1 protein expressions in PKCb 1 -transfected cells or vector control. No significant changes in protein expression of p53, c-myc, bax, bcl-2 and p27 kip1 were found in PKCb 1 -transfected or vector control cells with or without SC-236 treatment for 12 h.
Effect of antisense p21
waf1/cip1 on the anti-apoptotic effect of PKCb 1 PKC over-expression upregulated the protein expression of p21 waf1/cip1 . We co-transfected p21-antisense plasmid with PKCb 1 plasmid into AGS cells and compared the apoptotic response to SC-236. After cotransfection, the PKCb 1 -dependent up-regulation of p21 waf1/cip1 was blocked significantly at protein level (Figure 6b (c) Cells were pretreated with 10 mM AH6809 or 30 mM SC19220 followed by co-incubation with 25 mM SC-236 for another 12 h. Protein expression of PKCb 1 was determined by Western blot. (d) Cells were pretreated with 4 mg/ml PGE 2 or PGH 1 or PGH 2 followed by co-incubation with 25 mM SC-236 for another 12 h. Protein expression of PKCb 1 was determined by Western blot
Discussion
The regular use of various nonsteroidal anti-inflammatory drugs (NSAIDs) has been shown to decrease the incidence of gastrointestinal cancers (Dubois and Smalley, 1996; Thun, 1996; Gupta and DuBois, 1998) . This effect is thought to be caused predominantly by inhibition of cyclo-oxygenase-2 (COX-2) and, subsequently, prostaglandin synthesis (Richter et al., 2001; Won et al., 1998) . However, recent studies have suggested that COX-independent pathways may contribute considerably to these anti-proliferative effects. It is important to note that mechanisms contributed to the anti-tumor activity of NSAIDs, such as inhibition of cell cycle progression (Shiff et al., 1995; Goldberg et al., 1996) , induction of apoptosis (Barnes et al., 1998; Shao et al., 2000) and inhibition of angiogenesis (Tsujii et al., 1998; Jones et al., 1999) have been observed only at high concentrations of respective NSAIDs, which are 100-to 1000-fold higher than those needed to inhibit prostaglandin synthesis. Furthermore, NSAIDs inhibit tumor formation and growth in COXdeficient cell lines Hanif et al., 1996; Richter et al., 2001) . These data leave little doubt that cyclo-oxygenase-independent mechanisms account for part of the effects of certain NSAIDs, at least at high doses. Our present study showed that SC-236 (12.5 -50 mM) exhibited anti-tumor effect by induction of apoptosis in gastric cancer cells independent of COX-2 enzyme inhibition. The independence was supported by two of our findings. Firstly, although basal COX-2 and PGE 2 level in AGS was very low and 1 mM SC-236 already inhibited the TNF-a-induced PGE 2 production to less than 50%, the dose of induction for apoptosis was much higher than the one needed for the inhibition of COX-2. Secondly, exogenous prostaglandins including PGE 2 , PGH 1 and PGH 2 did not have any effect on COX-2 inhibitorsinduced apoptosis. These results indicated that the apoptotic effect was independent of the activity and specificity of the compound towards COX-2 isoenzyme. The significance of these in vitro studies was emphasized by a recent human study demonstrating 6 month treatment of 800 mg of celecoxib, a compound related to SC-236, leads to a significant reduction in the number of colorectal polyps (Steinbach et al., 2000) .
Recent studies have demonstrated that the antitumor effect by NSAIDs may act through other Novel target of COX-2 inhibitor X-H Jiang et al cellular targets besides COX inhibition. Possible candidates in this regard include 15-lipoxygenase-1 (Shureiqi et al., 2000) , arachidonic acid (Cao et al., 2000) , NF-kB (Weber et al., 2000) , or PPARd (Mitchell and Warner, 1999) . In this study, we showed that exposure of gastric cancer cells to the specific COX-2 inhibitor SC-236 decreased protein expression and kinase activity of PKCb 1 . To clarify whether the down-regulation of PKCb 1 was related to COX-2 inhibition, we used SC-288 (the derivative of SC-236 but without COX-2 inhibition effect). Interestingly, we found that SC-288 inhibited both protein expression and kinase activity of PKCb 1 , suggesting that the down-regulation of PKCb 1 might be independent of COX-2 inhibition. This result was further supported by the fact that neither of the exogenous prostaglandins could reverse the inhibitory effect on PKCb 1 by SC-236. Furthermore, to exclude the possibility that inhibition of PGE 2 directly regulated PKCb 1 expression through PGE 2 receptor, we used two PGE 2 receptors AH6809 (an EP1 and EP2 antagonist) and SC19220 (an EP1-selective antagonist). We showed that both AH6809 and SC19220 had no effect on basal or SC-236-treated PKCb 1 expression. Therefore, we concluded that the inhibition of PKCb 1 by SC-236 was a prostaglandin/cyclo-oxygenase-independent event. In addition, based on our previous study which showed that indomethacin suppressed the protein expression of PKCb 1 , but overexpressed PKCb 2 , Z and e (Zhu et al., 2000) , we suggest PKC might be another cellular target for NSAIDs to execute their anti-tumor effect. However, we also found that NS-398 and Nimesulide failed to inhibit PKCb 1 expression, suggesting a unique role of SC-236-related compounds in this regard.
PKC plays a major role in the regulation of cell growth, differentiation and apoptosis. The role of PKC waf1/cip1 , cells were treated with SC-236, apoptosis was determined by acridine orange staining in apoptosis is controversial. In this study, we showed that SC-236 down-regulated expression of PKCb 1 and overexpression of PKCb 1 suppressed SC-236-induced apoptosis in gastric cancer cells, which suggested that PKCb 1 acted as a survival mediator in response to SC-236 exposure. Several studies have suggested that classical and atypical PKC isoenzymes are associated with cell survival, whereas the novel PKC isozymes are pro-apoptotic in function (Deacon et al., 1997) . Among them, PKCb has been connected with increased cell survival in several cell systems. PKCb transfectants showed substantial protection from cell death induced by the exposure to NO donors in murine RAW 264.7 macrophage (Jun et al., 1997) . More recently, several studies showed a PKCb inhibitor had anti-angiogenic and anti-tumor effects against human cancer xenografts (Teicher et al., 2001b,c,d ). These studies raise the probability that PKCb could be a novel target for the treatment of gastric cancer. Our present study demonstrates that a novel class of drugs, SC-236, also execute their anti-tumor and apoptotic effects in gastric cancer through modulation of PKCb.
Our results showed that overexpression of PKCb 1 increased protein expression of p21 waf1/cip1 in the absence of presence of SC-236, which indicated that PKCb 1 was an upstream regulator that modulated expression of p21 waf1/cip1 in the signal transduction cascade. This finding was in accordance with our previous work (Zhu et al., 2000) and several other studies (Zeng and el-Deiry, 1996; Das et al., 2000; Sugibayashi et al., 2001) . Studies suggest that PKC activates the MEK-ERK pathway in a Raf-dependent manner (Kolch et al., 1993) , Raf-1/ MEK/ERK pathway also regulates expression of the p21 waf1/cip1 gene (Beier et al., 1999) . Therefore, it is possible that PKCb 1 overexpression activates the MAP kinase pathway and up regulates p21 waf1/cip1 expression in AGS cells. Akashi et al. (1999) showed that PMA markedly stabilized p21 waf1/cip1 mRNA and suggested that PMA treatment caused post-transcriptional accumulation of p21 waf1/cip1 . In our study, we found that overexpression of PKCb 1 increased both p21 waf1/cip1 mRNA (data not shown) and protein expression, which indicated that PKCb 1 regulated p21 waf1/cip1 by transcriptional mechanisms. Recently, p21 waf1/cip1 induction has been linked to phorbol ester-mediated growth inhibition and apoptosis in diverse cell models such as fibroblasts and intestinal epithelial cells (Livneh et al., 1998; Frey et al., 1997) . In our study, we found that inhibition of PKCb 1 -mediated overexpression of p21 waf1/cip1 by its antisense cDNA could partially inhibit the antiapoptotic effect of PKCb 1 . Therefore, PKCb 1 suppressed NSAIDs-induced apoptosis might be mediated by upregulation of p21 waf1/cip1 and overexpression of p21 waf1/ cip1 enhanced cell survival and protected against NSAIDs-induced apoptosis. These results underscore the utility of p21 waf1/cip1 as a potentially important target for anti-tumor treatment in gastric cancers. Further investigation of the mechanism of PKC-induced p21 waf1/ cip1 induction will be critically important for identifying more signaling molecules that may serve as additional targets for novel therapeutic agents.
In conclusion, a novel mechanism of COX-2 specific inhibitor SC-236 was observed in the present study to account for its anti-proliferative activity. Our data indicated that COX-2 inhibitor induced apoptosis by a novel cellular target which was not necessarily related to its COX enzyme and prostaglandins inhibition. COX-2 inhibitor-induced apoptosis in gastric cancer cells was mediated by the differential regulation of PKC isoforms. Overexpression of PKCb 1 suppressed COX-2 inhibitor-induced apoptosis possibly through up-regulation of p21 waf1/cip1 . PKCb 1 acted as a survival mediator in gastric cancer, and its down-regulation by COX-2 inhibitor SC-236 may provide new target for future treatment of gastric cancer.
Materials and methods
Reagents
SC-236 (a COX-2 specific inhibitor) and SC-288 (SC-236's derivative but devoid of COX-2 inhibition activity) were obtained from Searle (IL, USA). Stock solutions were made at the concentration of 100 mmol/l with absolute ethanol and diluted to working concentrations before use. The Prostaglandins (PGE 2 , PGH 1 , PGH 2 ) and PGE 2 antagonists (AH6809, SC19220) were purchased from Cayman chemical (Ann Arbor, MI, USA). The monoclonal antibodies against p21 waf1/cip1 (Ab-1) and c-myc (Ab-1) were purchased from Oncogene Research Products (Cambridge, MA, USA). Mouse monoclonal antibodies against p53 (1801), bcl-2 (100), bax (B-9), rabbit polyclonal antibodies against PKCa, b 1 , b 2 , g, e, d, i, Z, m, z, l, y and goat polyclonal antibody p21 kip1 (c19), COX-1, COX-2 and horseradish peroxidase-conjugated anti-rabbit, anti-mouse and anti-goat immunoglobulin IgG were obtained from Santa Cruz Biotechnology (Santa-Cruz, CA, USA).
Plasmids
To create the pBabe-PKCb 1 plasmid, a 2.016-kilobase (kb) BamHI fragment containing the entire coding region of rat PKCb 1 cDNA was ligated into a BamHI site downstream of the SV40 early promoter of the pBabe vector. pcDNA-asp21 was created by inserting a 517 bp BamHI/HindIII fragment (Zhu et al., 2000) containing the p21 waf1/cip1 coding region in the antisense orientation into the mammalian expression vector pcDNA3.1(+) (Invitrogen, Carlsbad, CA, USA).
Cell culture and transient transfection
AGS, a gastric adenocarcinoma cell line was purchased from the American Type Culture Collection (ATCC, Rockville, MD, USA). Cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 mg/ml streptomycin (Gibco BRL, Life Technologies, NY, USA) in a humidified atmosphere of 95% air with 5% CO 2 at 378C as a monolayer. For transient transfection, cells were seeded 24 h before transfection in 6-well plates at a density of 2610 5 /well, transfection with the indicated vector was carried out using lipofectamine 2000 (Gibco BRL, Life Technologies, NY, USA) as described in the manufacturer's protocol. In each transfection, 4 mg plasmid DNA was used per 6 mg lipofectamine 2000. After 4 h transfection, cells were refed with normal medium and allowed to recover overnight. After 24 h transfection, the cells were further treated by different concentrations of SC-236 or SC-288. Transfection efficiency and reproducibility was determined in parallel plates by transfection of the pSVb-Galactosidase control vector (Promega, Madison, WI, USA) and subsequent measuring of b-Galactosidase activity using b-Galactosidase enzyme assay system (Promega, Madison, WI, USA).
Acridine orange staining
Single cell suspensions were fixed in 1% formalin/PBS and stained with acridine orange (AO, 10 mg/ml, Sigma, St. Louis, MO, USA). Cells were spotted on glass slides and visualized under fluorescence microscope. Apoptotic cells were defined as cells showing cytoplasmic and nuclear shrinkage and chromatin condensation or fragmentation morphologically. At least 300-cells/field were counted to determine the apoptotic index.
DNA fragmentation analysis
Briefly, cell pellets were lysed in 10 mM Tris-HCl (pH 7.4) buffer containing 25 mM EDTA, 0.5% SDS and 0.1 mg/ml proteinase K (Sigma) and incubated at 508C for 12 -18 h. DNA was extracted with an equal volume of phenol/ chloroform/isoamyl alcohol (25 : 24 : 1) and precipitated with two volumes of ice-cold absolute ethanol and 1/10 volume 3M sodium acetate. Equal amounts (10 mg per well) of DNA were electrophoresed in 1.8% agarose gels impregnated with ethidium bromide (0.1 mg/ml) for 2 h at 80 V. DNA fragments in the form of laddering pattern were visualized by ultraviolet transillumination.
Western blotting
The whole cell lysates were extracted with lysis buffer containing 1% Triton-100, 50 mM sodium chloride, 50 mM sodium fluoride, 20 mM Tris (pH 7.4), 1 mM EDTA, 1 mM EGTA, 1 mM sodium vanadate, 0.2 mM phenylmethylsulfonyl fluoride and 0.5% Nonidet P-40. Western blotting was carried out as described previously (Li et al., 1996) . In brief, equal amount of cell lysates (20 -60 mg) were solubilized in 10% sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS -PAGE) and transferred onto nitrocellulose membranes (Sigma, St. Louis, MO, USA). After blocking, the membranes were incubated with the appropriate diluted primary antibody. Proteins were detected by the enhanced chemiluminescence (ECL) detection system (Amersham, Bucks, UK).
Kinase activity assay
Subconfluent monolayers cells (in 100 mm plates) were washed with PBS and resuspended in cold lysis buffer (50 mM Tris/HCl, pH 7.5, 0.3% b-mercaptoethanol, 5 mM EDTA, 10 mM EGTA, 50 mg/ml PMSF) for 10 min and then were homogenized by repeated aspiration through a 21-gauge needle. Cell debris was removed by centrifugation at 14 000 r.p.m. at 48C for 15 min. Two mg of anti PKCb 1 polyclonal antibody was added to the supernatant and incubated for 1 h at 48C. Agarose-conjugated protein A was added and incubated for another 1 h. The kinase activity assay was carried out using a Protein Kinase C Enzyme Assay kit (Amersham, Bucks, UK). Twenty-five ml of assay mixture and 0.2 mCi of [g-32 P]ATP were added to each immunoprecipitation sample and incubated for 15 min at 378C. Peptide binding papers were used to separate phosphorylated peptide. The papers were washed with 5% acetic acid and then transferred to scintillation vials for 32 P counting.
Prostaglandin E 2 production
Cells were plated at 5610 4 /well into 24-well plates. Twentyfour hours later, the cultures were pretreated by SC-236 or SC-288 for 2 h, then followed by further treatment with TNF-a for another 12 h. PGE 2 secreted into the medium was determined by competitive Elisa using a kit from Cayman Chemicals (Ann Arbor, MI, USA) according to the manufacturer's instructions. Briefly, medium from the cultured cells were added to 96-well plates coated with an anti-mouse antibody, mixed with a PG/acetylcholinesterase tracer and a monoclonal antibody against prostaglandin and incubated at 48C overnight. Unbound PG/acetylcholinesterase was removed and washed extensively. Bound acetylcholinesterase was detected by Ellman's reagent and measured at 410 nm.
Statistical analysis
The data shown were mean values of at least three different experiments and expressed as mean+s.e.m. Student's t-test was used to compare the result. A P-value of less than 0.05 is considered statistically significant.
Abbreviations
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